

Signed an Exclusive Distributorship Agreement with Texcell

Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama) ("SPI") has signed an exclusive distributorship agreement with Texcell Japan (based at Kobe Biomedical Innovation Center, providing local technical and quality support), member of the Texcell Group (Head Office: France; CEO: Eric Henriet Ph.D.), a France-based company providing certified cell-banking and biosafety services following Good Manufacturing Practices (GMP) or Good Laboratory Practices (GLP) for pharmaceuticals and biological products.

Promoting of cell/gene therapy development for practical use, and diversifying of modalities, the recent trend of pharmaceutical industry, has led to the development of increasing numbers of biological products in Japan. Since June 2023, SPI formed the New Modalities Support Group, strengthening the support for the pharmaceutical development specifically in the antibody, exosome and nucleic acid therapeutics. Under such circumstances, GMP cell-banking and GMP/GLP biosafety services, which Texcell provides, are necessary pieces in the upstream of pharmaceutical manufacturing. SPI has been providing with contract manufacturing, downstream of pharmaceutical manufacturing, and with the addition of Texcell's services, SPI is able to full-support customers through the pharmaceutical manufacturing processes.

Texcell is a Contract Research Organization (CRO) established in 2003 based on the organization spun off from the Pasteur Institute in 1987, providing with GMP cell-banking, biosafety services and several assays to support through non-clinical to market phase. Texcell's services are GMP/GLP certified, audited by FDA and EMA. Particularly, GLP grade viral clearance testing and viral safety is performed since the Pasteur Institute era, more than 35 years of experiences have shaped Texcell's service characteristics such as availability to handle numerous viruses, and compatibleness with various product forms, antibody, blood/plasma-derived, gene/cell therapy products and medical devices. In 2023, Texcell has established a new facility in China and expanded the facility in the US. By cooperating with the existing facilities in Germany (Vivo Science, a Texcell Company) as well, Texcell is working on the strengthening of the stable and worldwide service delivery.

SPI is committed to working with Texcell to further promote pharmaceutical research and development in Japanese market.

[Contact]

Summit Pharmaceuticals International Corporation

Discovery & Alliance Coordination Dept. New Modalities Support Group

Tel : +81-3-5220-1560

Email : alliance@summitpharma.co.jp